Products :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and …
Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.
Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and …
Who We Are :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and …
Management Team :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and …
Investor Relations :: Rigel Pharmaceuticals, Inc. (RIGL)
Dec 7, 2025 · Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune …
News & Events :: Rigel Pharmaceuticals, Inc. (RIGL)
Dec 8, 2025 · Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635 (c) (4) Corporate Presentation January 2026 Recent Events View All Events
Rigel Provides Business Update and 2025 Outlook
Jan 13, 2025 · Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289 in patients with relapsed or refractory (R/R) lower …
Press Releases :: Rigel Pharmaceuticals, Inc. (RIGL)
Dec 7, 2025 · Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition Nov 26, 2025 8:05am …
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
Feb 22, 2024 · Rigel expects to complete the transition of the asset and start recognizing product sales in the third quarter of 2024. Rigel will provide additional details on this transaction at its upcoming …